Royal Fund Management, LLC Neurocrine Biosciences Inc Transaction History
Royal Fund Management, LLC
- $1.04 Billion
- Q4 2024
Shares
2 transactions
Others Institutions Holding NBIX
# of Institutions
643Shares Held
94.3MCall Options Held
634KPut Options Held
603K-
Black Rock Inc. New York, NY14.2MShares$1.69 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10MShares$1.19 Billion0.02% of portfolio
-
State Street Corp Boston, MA5.15MShares$612 Million0.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.57MShares$306 Million0.47% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.86MShares$221 Million3.62% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $11.4B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...